About Inside Therapeutics:

Thomas holds a PhD in biology (2012, Université Paris-Saclay) and a master’s degree in Innovation Management.

He joined Cherry Biotech at its founding (2014), an Elvesys spin-off specialized in organoids and organ-on-a-chip instruments and services. He managed various functions including industrialization, business administration, innovative project management, financial reporting, scientific publications, as well as sales and marketing scale-up.

He held the position of COO from 2017 to 2019. From 2019 to 2022, he joined Elvesys as CMO and Executive Board member with a particular mission of transition management during the company’s scale-up momentum (x2 turnover and employees).

He is currently the CEO (Chief Executive Officier) of Inside Therapeutics.

Audrey is a nanoparticle Ph.D. graduate. She originally has a physics engineering background from the University of Louvain, before specializing in nanotechnologies and bioengineering at Polytechnique Montreal.
During her PhD, she specifically studied the nucleation and physics of lipid nanoparticles and liposome formation. Her work led to the patent at the heart of Inside Therapeutics’ project.
Audrey is the CSO (Chief Scientific Officer) at Inside Therapeutics

Robin is a micro/nanotechnology engineer who graduated with a dual degree from INP Grenoble and EPFL in 2015. His acquired skills and expertise paved the way for a move to the United States (Georgia Institute of Technology, IBM San Francisco). Robin quickly oriented his career towards technical sales and business, first at Resolution Spectra Systems until 2017, before moving to Hong Kong where he worked to identify business partners for French tech companies.

He joined Elvesys in 2018 and successfully applied his dual technical and business skills as a sales engineer. He took over the position of Head of Sales in 2019, during which Elvesys doubled its turnover between 2020 and 2022.

He is currently the CBO (Chief Business Officer) at Inside Therapeutics.

Hélène Beaupied holds a Master’s degree in Cellular and Molecular Biology.

With over 20 years of experience in industrialization, she has made significant contributions to Pall Genedisc Technologies, a biotech company specializing in the design and manufacture of PCR equipment and consumables for detecting microorganisms in the food & beverage and environmental markets. In her roles as a team manager and Board member, Hélène played a crucial part in shaping the company’s strategy, overseeing industrialization processes, and collaborating with the R&D, Quality Control, Quality Assurance, and Production departments.
Leveraging her extensive and diverse experience, Hélène joined Inside Tx in June 2024 as the ISC-Q Manager.

Her exceptional leadership and strategic vision led to her appointment as COO (Chief Operating Officer) in May 2025.

Matthieu is a Fluid Mechanics and Automation engineer by trade who graduated from Ecole Centrale (1999, Lyon).

He held financial engineering positions from 2001 to 2009 throughout Europe and the United States. Matthieu then returned to France and joined the Ecole Centrale in Nantes to do his thesis work in numerical simulation applied to fluid mechanics.
He then seized an entrepreneurial opportunity and founded Advanced Aerodynamic Vessels in 2013, which he managed until 2022. He handled the whole project (structuring, fund raising, R&D…) as CEO until the realization of a functional prototype and the delivery of 3 innovative commercial ships (fast and low energy consumption).

He currently is the CTO (Chief Technical Officer) of Inside Therapeutics

Rebecca brings over 15 years of international experience in corporate operations and business administration, with a background spanning organisations in the UK, France, and across multiple regions.

Her expertise lies in developing scalable systems within fast-growing companies — across finance, HR, and corporate affairs — ensuring compliance, informing decisions, and supporting sustainable growth.

She joined Inside Therapeutics in 2024 as MCO (Manager Corporate Operations).

Alexis is an EDHEC Business School (1996) graduate, he holds an MBA (2008, Imperial College London), and has accumulated more than 25 years of experience in the biotech field.

In 2014, he joined the biotech OSE Immunotherapeutics as Director of Operations. He led the business development with pharmaceutical companies and built the financing plan until an IPO (Euronext) in 2015 allowing a financing of 21 million euros for the company. Alexis became the CEO of OSE Immunotherapeutics in 2018 and continued the company’s development by signing immunotherapy development licenses with Servier, Boehringer Ingelheim and Veloxis and securing the company’s drug development pipeline.

At Inside Therapeutics, Alexis acts as CFO (Chief Financial Officer) and chairman of the board